126 related articles for article (PubMed ID: 33092905)
21. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
22. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.
Jung ME; Byun BJ; Kim HM; Lee JY; Park JH; Lee N; Son YH; Choi SU; Yang KM; Kim SJ; Lee K; Kim YC; Choi G
Bioorg Med Chem Lett; 2016 Jun; 26(11):2719-23. PubMed ID: 27106709
[TBL] [Abstract][Full Text] [Related]
23. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
26. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
Kolb P; Kipouros CB; Huang D; Caflisch A
Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors.
Chekanov MO; Ostrynska OV; Synyugin AR; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):338-43. PubMed ID: 23578312
[TBL] [Abstract][Full Text] [Related]
28. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
30. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent indicator displacement assays to identify and characterize small molecule interactions with RNA.
Wicks SL; Hargrove AE
Methods; 2019 Sep; 167():3-14. PubMed ID: 31051253
[TBL] [Abstract][Full Text] [Related]
32. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
[TBL] [Abstract][Full Text] [Related]
33. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
35. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening.
Piala AT; Akella R; Potts MB; Dudics-Giagnocavo SA; He H; Wei S; White MA; Posner BA; Goldsmith EJ
Bioorg Med Chem Lett; 2016 Aug; 26(16):3923-7. PubMed ID: 27426302
[TBL] [Abstract][Full Text] [Related]
37. MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing.
Kim JS; Kim EJ; Kim HS; Kurie JM; Ahn YH
Biochem Biophys Res Commun; 2017 Sep; 491(2):337-342. PubMed ID: 28733031
[TBL] [Abstract][Full Text] [Related]
38. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
39. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel scaffolds for Rho kinase 2 inhibitor through TRFRET-based high throughput screening assay.
Oh KS; Mun J; Cho JE; Lee S; Yi KY; Lim CJ; Lee JS; Park WJ; Lee BH
Comb Chem High Throughput Screen; 2013 Jan; 16(1):37-46. PubMed ID: 22934984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
